Philip T Ninan

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi request reprint High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial
    Philip T Ninan
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1841 Clifton Road, Atlanta, GA 30329, USA
    J Clin Psychiatry 67:15-22. 2006
  2. ncbi request reprint Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue
    Philip T Ninan
    Department of Psychiatry, Emory University School of Medicine, 1841 Clifton Road, Suite 400 North, Atlanta, GA 30329, USA
    J Clin Psychiatry 65:414-20. 2004
  3. ncbi request reprint Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine
    Philip T Ninan
    Department of Psychiatry, Emory University, Atlanta, GA 30329, USA
    Psychopharmacol Bull 37:89-96. 2003
  4. ncbi request reprint Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30307, USA
    J Clin Psychopharmacol 27:614-9. 2007
  5. ncbi request reprint Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, 1725 W Harrison Street, Suite 955, Chicago, IL 60612, USA
    J Clin Psychiatry 63:709-16. 2002
  6. ncbi request reprint Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
    J Clin Psychiatry 68:1014-23. 2007
  7. ncbi request reprint Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213 2593, USA
    J Clin Psychiatry 63:493-500. 2002
  8. pmc Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, USA
    Arch Gen Psychiatry 66:1178-88. 2009
  9. ncbi request reprint Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not
    Alan F Schatzberg
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5717, USA
    Arch Gen Psychiatry 62:513-20. 2005
  10. pmc Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322
    Proc Natl Acad Sci U S A 100:14293-6. 2003

Detail Information

Publications34

  1. ncbi request reprint High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial
    Philip T Ninan
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1841 Clifton Road, Atlanta, GA 30329, USA
    J Clin Psychiatry 67:15-22. 2006
    ..To evaluate the efficacy and safety of high-dose sertraline for patients with obsessive-compulsive disorder (OCD) who failed to respond to standard sertraline acute treatment...
  2. ncbi request reprint Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue
    Philip T Ninan
    Department of Psychiatry, Emory University School of Medicine, 1841 Clifton Road, Suite 400 North, Atlanta, GA 30329, USA
    J Clin Psychiatry 65:414-20. 2004
    ..This open-label study evaluated the efficacy and safety of modafinil treatment initiated with an SSRI in patients with MDD and fatigue...
  3. ncbi request reprint Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine
    Philip T Ninan
    Department of Psychiatry, Emory University, Atlanta, GA 30329, USA
    Psychopharmacol Bull 37:89-96. 2003
    ..Because of their safety and beneficial adverse-event profile, the SSRIs have become the leading choice in the pharmacological management of OCD...
  4. ncbi request reprint Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30307, USA
    J Clin Psychopharmacol 27:614-9. 2007
    ..Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue...
  5. ncbi request reprint Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, 1725 W Harrison Street, Suite 955, Chicago, IL 60612, USA
    J Clin Psychiatry 63:709-16. 2002
    ..This study compares the effects of antidepressant medication, psychotherapy, and combined treatment on sexual interest/satisfaction and function in patients with chronic major depression...
  6. ncbi request reprint Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
    J Clin Psychiatry 68:1014-23. 2007
    ..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression...
  7. ncbi request reprint Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213 2593, USA
    J Clin Psychiatry 63:493-500. 2002
    ..As nefazodone-mediated blockade of serotonin-2 receptors may directly relieve insomnia associated with depression, we examined the more specific effects of CBASP and nefazodone, singly and in combination, on sleep disturbances...
  8. pmc Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, USA
    Arch Gen Psychiatry 66:1178-88. 2009
    ..Previous studies have found that few chronically depressed patients remit with antidepressant medications alone...
  9. ncbi request reprint Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not
    Alan F Schatzberg
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5717, USA
    Arch Gen Psychiatry 62:513-20. 2005
    ..Although various strategies are available to manage nonresponders to an initial treatment for depression, no controlled trials address the utility of switching from an antidepressant medication to psychotherapy or vice versa...
  10. pmc Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322
    Proc Natl Acad Sci U S A 100:14293-6. 2003
    ..Our results suggest that psychotherapy may be an essential element in the treatment of patients with chronic forms of major depression and a history of childhood trauma...
  11. ncbi request reprint The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9086, USA
    Biol Psychiatry 54:573-83. 2003
    ..The QIDS-SR(16) has highly acceptable psychometric properties, which supports the usefulness of this brief rating of depressive symptom severity in both clinical and research settings...
  12. ncbi request reprint REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: rationale and design
    Madhukar H Trivedi
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Psychopharmacol Bull 41:5-33. 2008
    ....
  13. ncbi request reprint Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination
    Philip T Ninan
    Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
    J Clin Psychiatry 63:434-41. 2002
    ....
  14. ncbi request reprint The state of knowledge of chronic depression
    Alan J Gelenberg
    Department of Psychiatry, Arizona Health Sciences Center, Tucson, AZ, USA
    J Clin Psychiatry 67:179-84. 2006
  15. ncbi request reprint A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder
    Eric Hollander
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Clin Psychiatry 64:640-7. 2003
    ....
  16. doi request reprint A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders
    Mark S George
    Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Brain Stimul 1:112-21. 2008
    ....
  17. ncbi request reprint Report by the ACNP Task Force on response and remission in major depressive disorder
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
    Neuropsychopharmacology 31:1841-53. 2006
    ..Research to evaluate these recommendations empirically is needed...
  18. ncbi request reprint An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder
    Michael E Thase
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    CNS Spectr 14:144-54. 2009
    ..To assess the efficacy of desvenlafaxine (administered as desvenlafaxine succinate) in outpatients with major depressive disorder...
  19. ncbi request reprint Tiagabine for social anxiety disorder
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    Hum Psychopharmacol 22:241-4. 2007
    ..Results of this pilot study suggest that tiagabine may be an option for the treatment of patients with SAD. Larger, controlled studies are required to fully elucidate the potential of tiagabine for the treatment of SAD...
  20. pmc The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder
    Steven J Garlow
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Psychiatr Res 46:1406-13. 2012
    ..To determine whether the combination of triiodothyronine (T3) plus sertraline at treatment initiation confers greater antidepressant efficacy than sertraline plus placebo in patients with major depressive disorder...
  21. pmc Recovery and subsequent recurrence in patients with recurrent major depressive disorder
    Boadie W Dunlop
    Emory University School of Medicine, 1256 Briarcliff Road, Building A, 3rd Floor, Atlanta, GA 30322, USA
    J Psychiatr Res 46:708-15. 2012
    ..We conclude that protection against recurrence derives from the degree and duration of recovery, particularly for patients maintained on antidepressant medication...
  22. ncbi request reprint New developments in the neurobiological basis of anxiety disorders
    Jack M Gorman
    Department of Psychiatry, Columbia University, New York, New York 10032, USA
    Psychopharmacol Bull 36:49-67. 2002
    ....
  23. ncbi request reprint Use of dialectical behavior therapy in borderline personality disorder: a view from residency
    Binali Sharma
    Emory University School of Medicine, Atlanta, Georgia, USA
    Acad Psychiatry 31:218-24. 2007
    ..The authors describe the use of dialectical behavior therapy (DBT) in treating borderline personality disorder during psychiatry residency, and assess the status of DBT education within psychiatry residencies in the United States...
  24. ncbi request reprint Social anxiety disorder and the neurobiology of social relationships
    Philip T Ninan
    Department of Psychiatry and Behavioral Sciences, Mood and Anxiety Disorders Program, Emory University School of Medicine, Atlanta, GA, USA
    Psychopharmacol Bull 36:94-101. 2002
    ..Understanding the neural circuitry mediating social relationships and its role in the threat response in SAD may be important for the development of new treatments for this disorder...
  25. ncbi request reprint New insights into the diagnosis and pharmacologic management of generalized anxiety disorder
    Philip T Ninan
    Mood and Anxiety Disorders Program, Emory University School of Medicine in Atlanta, GA, USA
    Psychopharmacol Bull 36:105-22. 2002
    ..Some antidepressants have been shown to better facilitate remission. This article will summarize evidence for the clinical utility of pharmacotherapeutic agents commonly used in the treatment of GAD...
  26. pmc A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
    Neuropsychopharmacology 37:2830-6. 2012
    ..24, p=0.034) and response rate (β=2.26, p=0.035). Including a higher proportion of academic sites may increase the ability to detect differences between active drug and placebo in clinical trials of major depressive disorder...
  27. ncbi request reprint Neurobiology and etiology of panic disorder
    Philip T Ninan
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA
    J Clin Psychiatry 66:3-7. 2005
    ..The lessons learned can guide the delivery of treatments to enhance the likelihood of achieving remission and the discovery of novel treatments for panic disorder...
  28. ncbi request reprint New goals in the treatment of depression: moving toward recovery
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Psychopharmacol Bull 36:24-35. 2002
    ..Compared with TCAs, the better safety profile of venlafaxine has established the drug as a more appropriate first-line treatment option...
  29. ncbi request reprint Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination
    Robert M A Hirschfeld
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, Texas 77555 0188, USA
    Biol Psychiatry 51:123-33. 2002
    ..This study compared efficacy of nefazodone, psychotherapy, and their combination in improving psychosocial functioning in chronically depressed outpatients...
  30. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases
    Martin B Keller
    Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
    J Clin Psychiatry 68:1246-56. 2007
    ..To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression...
  31. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases
    Martin B Keller
    Brown University, Providence, Rhode Island 02906, USA
    Biol Psychiatry 62:1371-9. 2007
    ..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment...
  32. ncbi request reprint Integrating neurobiology and psychopathology into evidence-based treatment of social anxiety disorder
    Michael R Liebowitz
    Anxiety Disorders Clinic, New York State Psychiatric Institute, New York City, USA
    CNS Spectr 10:suppl13 1-11; discussion 12-3; quiz 14-5. 2005
    ..The prevalence, rates of recognition and treatment, patterns of comorbidity, quality-of-life issues, and natural history of SAD are discussed as well as pharmacologic and psychosocial treatment strategies for SAD...
  33. ncbi request reprint Psychosocial context of antidepressant response
    Boadie W Dunlop
    Biol Psychiatry 57:314; author reply 314-5. 2005
  34. ncbi request reprint Selective publication of antidepressant trials
    Philip T Ninan
    N Engl J Med 358:2181; author reply 2181-2. 2008